ORIC Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
ORIC Pharmaceuticals has a total shareholder equity of $274.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $302.1M and $28.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$272.37m |
| Equity | US$273.99m |
| Total liabilities | US$28.08m |
| Total assets | US$302.07m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4TZ's short term assets ($279.4M) exceed its short term liabilities ($21.2M).
Long Term Liabilities: 4TZ's short term assets ($279.4M) exceed its long term liabilities ($6.8M).
Debt to Equity History and Analysis
Debt Level: 4TZ is debt free.
Reducing Debt: 4TZ has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4TZ has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4TZ has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 24.3% each year.